- Home
- PLCE vs NRXS Comparison
PLCE vs NRXS Comparison
Compare PLCE & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLCE | NRXS |
|---|---|---|
| Founded | 1969 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.8M | 78.9M |
| IPO Year | 1997 | 2023 |
Fundamental Metrics
Financial Performance| Metric | PLCE | NRXS |
|---|---|---|
| Price | $3.36 | $7.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.50 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 514.2K | 135.5K |
| Earning Date | 04-10-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.48 | ★ 22.13 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | $4.41 | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $2.76 | $1.94 |
| 52 Week High | $9.56 | $7.97 |
Technical Indicators
Market Signals| Indicator | PLCE | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 46.49 | 63.25 |
| Support Level | $2.86 | $6.58 |
| Resistance Level | $3.74 | N/A |
| Average True Range (ATR) | 0.34 | 0.53 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 36.59 | 71.25 |
Price Performance
Historical ComparisonAbout PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).